Thomas Gad - Y MAbs Chairman
| YMAB Stock | USD 11.92 0.04 0.34% |
Chairman
Mr. Thomas Gad is the Chairman of the Board, President, Founder, Head of Business Development and Strategy of the Company. Mr. Gad founded our Company in April 2015 and has served as our Chairman, President and Head of Business Development and as a member of our Board of Directors since our inception. Mr. Gad founded our Company inspired by his daughter, who went through six years of various cancer treatments before receiving breakthrough cancer immunotherapy at MSK and overcoming highrisk neuroblastoma. He was also responsible for securing executive management and seed capital for our Company. Mr. Gad has more than 12 years of industry experience in the pharmaceutical industry, including business development, senior management, financing and licensing negotiations and manufacturing site qualification. Mr. Gad was the founder and sole owner of YmAbs Holding, ApS, a personal holding company involved in research and development activities in the pharmaceutical industry from 2014 until the company was placed in liquidation proceedings in 2015. The company is now under compulsory dissolution proceedings. This company is unrelated to our Company. He was the cofounder of Singad Pharma, a Danish specialty pharmaceutical and distribution company, from 2003 to 2013. Prior to that, Mr. Gad worked with Aspen Capital PartnersFFC AS in investment banking from 1998 to 2003 and has extensive experience in raising capital for publicly listed companies
| Age | 54 |
| Address | 230 Park Avenue, New York, NY, United States, 10169 |
| Phone | 646 885 8505 |
| Web | https://www.ymabs.com |
Latest Insider Transactions
| 2024-09-16 | Disposed of 30000 shares @ 12.97 | View | |
| 2024-09-13 | Disposed of 65000 shares @ 13.47 | View | |
| 2024-06-10 | Disposed of 35000 shares @ 12.03 | View | |
| 2024-05-23 | Disposed of 7351 shares @ 13 | View | |
| 2024-05-21 | Disposed of 25000 shares @ 12 | View | |
| 2023-12-15 | Disposed of 50000 shares @ 6.61 | View | |
| 2023-12-13 | Disposed of 50000 shares @ 6.58 | View |
Thomas Gad Latest Insider Activity
Tracking and analyzing the buying and selling activities of Thomas Gad against Y MAbs stock is an integral part of due diligence when investing in Y MAbs. Thomas Gad insider activity provides valuable insight into whether Y MAbs is net buyers or sellers over its current business cycle. Note, Y MAbs insiders must abide by specific rules, including filing SEC forms every time they buy or sell Y MAbs'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Thomas Gad over two months ago Disposition of 22831 shares by Thomas Gad of Y MAbs at 4.38 subject to Rule 16b-3 | ||
Thomas Gad over two months ago Disposition of 30000 shares by Thomas Gad of Y MAbs at 12.97 subject to Rule 16b-3 | ||
Thomas Gad over two months ago Disposition of 65000 shares by Thomas Gad of Y MAbs at 13.47 subject to Rule 16b-3 | ||
Thomas Gad over three months ago Disposition of 00 shares by Thomas Gad of Y MAbs at 16.44 subject to Rule 16b-3 |
Y MAbs Management Efficiency
The company has return on total asset (ROA) of (0.1198) % which means that it has lost $0.1198 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2478) %, meaning that it created substantial loss on money invested by shareholders. Y MAbs' management efficiency ratios could be used to measure how well Y MAbs manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.18. In addition to that, Return On Capital Employed is expected to decline to -0.25. At present, Y MAbs' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 129.5 M, whereas Other Current Assets are forecasted to decline to about 4.9 M.Similar Executives
| Found 1 records | CHAIRMAN Age | ||
| Andrew MD | Eliem Therapeutics | 47 | |
Management Performance
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.12 |
Y mAbs Therapeutics Leadership Team
Elected by the shareholders, the Y MAbs' board of directors comprises two types of representatives: Y MAbs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of YMAB. The board's role is to monitor Y MAbs' management team and ensure that shareholders' interests are well served. Y MAbs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Y MAbs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Courtney Dugan, Vice Relations | ||
| Susan Smith, Senior Officer | ||
| Thomas Gad, Chairman of the Board and Presidentident, Founder, Head of Business Development and Strategy | ||
| MBBS MBA, Senior Officer | ||
| Torben MSc, VP Operations | ||
| Michael Rossi, President CEO | ||
| Sue Smith, VP Officer | ||
| Peter CPA, CFO Treasurer | ||
| Joris Wilms, COO, Senior Vice President | ||
| MSc MD, Senior Officer | ||
| Bo Kruse, CFO, Treasurer, Secretary, Director | ||
| FACNP FACP, Chief Officer |
YMAB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Y MAbs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.43) % | ||||
| Current Valuation | 465.05 M | ||||
| Shares Outstanding | 44.79 M | ||||
| Shares Owned By Insiders | 12.21 % | ||||
| Shares Owned By Institutions | 72.24 % | ||||
| Number Of Shares Shorted | 3.63 M | ||||
| Price To Book | 5.76 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Y mAbs Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Y MAbs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Y Mabs Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Y Mabs Therapeutics Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Revenue Per Share 1.921 | Quarterly Revenue Growth (0.1) | Return On Assets (0.12) | Return On Equity (0.25) |
The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.